PitchBook-创新焦点_肾去极化（英）-2025_6页_7mb

Renal Denervation (RDN) Innovation Summary

Core Content

Renal denervation (RDN) is an emerging medical technology aimed at treating uncontrolled hypertension by disrupting overactive sympathetic nerves in the renal arteries. This innovation has gained significant attention due to a proposed CMS coverage decision, which could drive broader adoption in the US and global healthcare systems. The technology is primarily delivered through two modalities: ultrasound-based renal denervation (uRDN) and radio-frequency-based renal denervation (rfRDN). Key players in the RDN market include Medtronic, Recor Medical, Boston Scientific, and DeepQure, with Geneticure also playing a pivotal role in addressing nonresponse challenges.

Main Points

1. CMS Coverage and Market Potential

• CMS proposed coverage for RDN in July 2025, marking a major milestone for the field.
• This decision is expected to expand patient access and encourage private insurers to follow, potentially leading to broad adoption in the US and globally.
• The final determination is anticipated by October 2025, with a high likelihood (above 90%) of a positive outcome due to the lack of alternatives for uncontrolled hypertension and the high safety profile of RDN procedures.
• Market size is projected to exceed $1 billion over the next decade in the US.

2. RDN Technology and Devices

• RDN lowers blood pressure by targeting sympathetic nerves, reducing blood flow and pressure.
• uRDN and rfRDN are the two primary delivery methods.
• Medtronic offers the Symplicity Spyral rfRDN system, which received FDA approval in November 2023 despite failing a key efficacy endpoint in a 2022 trial.
• Recor Medical developed the Paradise uRDN platform, which had a smoother regulatory path and received favorable FDA panel votes in 2023.
• SoniVie was acquired by Boston Scientific in March 2025. Its TIVUS system is an ultrasound-based uRDN device that avoids direct contact with artery walls, potentially reducing complications and improving procedure speed.
• DeepQure is based in Seoul and offers the HyperQure system, delivering RF energy from outside the vessel wall for more consistent nerve ablation.

3. Deal Activity and Funding

• Total VC funding raised by RDN startups since 2015 is $418.7 million, with $95.3 million raised in 2021, reflecting peak VC interest.
• Major deals include:
  • Ablative Solutions’ Series D2 in 2022 ($91.4M)
  • SyMap Medical’s Series E in 2021 ($80M)
  • SoniVie’s Series C in 2023 ($60M), followed by its acquisition by Boston Scientific.
• Strategic acquisitions have been a key trend, with Boston Scientific acquiring SoniVie and Otsuka Holdings acquiring Recor Medical.
• Top investors include TechWald Holding, Aphelion Capital, and Fairview Health Services, which have participated in multiple RDN deals.

4. Nonresponse and Precision Medicine

• Nonresponse rates in RDN trials can reach up to 30%, limiting the treatment’s effectiveness for some patients.
• Geneticure, a pharmacogenomics company, has secured a patent in July 2025 that enables the analysis of genetic data to predict patient response to RDN.
• This technology could become a critical enabler of precision medicine in the RDN space, as no clinically approved method currently exists for predicting RDN outcomes.

Key Players and Their Contributions

Conclusion

Renal denervation is poised to become a transformative treatment for uncontrolled hypertension, with CMS coverage playing a crucial role in its adoption. Despite challenges such as nonresponse rates, the technology is advancing through diverse device innovations and strategic investments. The market is expected to grow significantly over the next decade, driven by the entry of multiple players and the potential for precision medicine solutions like those from Geneticure.